Remedy for disease of neuropathy


PURPOSE: A drug useful for remedying various kinds of diseases caused by disorder of peripheral nervous system or central nervous system, comprising GQ 1b , etc., molecular kinds of ganglioside as an active ingredient. CONSTITUTION: A drug effective for diseases (e.g., inflammatory neuritis, multiple neuritis, Giran Barrrett syndrome, diabetic or alcoholic neuropathy, facial palsy, etc.) caused by disorder of peripheral nervous system or central nervous system, containing GQ 1b alone or a mixture of GQ 1b and GD 1a or GD 1b among GQ 1b , GD 1a and GD 1b , molecular kinds of ganglioside. Administration can be carried out orally or parenterally, and intramuscular injection, intravenous injection, hypodermic injection, and intra-abdominal injection are preferable. A dose is preferably 0.1W20mg in case of GQ 1b alone, and, when it is blended with GD 1a or GD 1b , 1W10 times, preferably 3W6 times as much Gd 1a or GD 1b as GQ 1b by weight is preferable. COPYRIGHT: (C)1984,JPO&Japio




Download Full PDF Version (Non-Commercial Use)

Patent Citations (1)

    Publication numberPublication dateAssigneeTitle
    JP-S5234912-AMarch 17, 1977Fidia SpaExtraction of ganglioside and application of same to new medicines

NO-Patent Citations (0)


Cited By (5)

    Publication numberPublication dateAssigneeTitle
    CN-103040976-AApril 17, 2013陈淑香Medicine for promoting postoperative rehabilitation of facial nerve injury surgical anastomosis
    EP-0260606-A2March 23, 1988Mect Corporation, MITSUI TOATSU CHEMICALS, Inc.Sialocylglycerolipid enthaltendes Arzneimittel zur Heilung von neurotischer Störung oder Krankheit
    EP-0719557-A1July 03, 1996SynthelaboUtilisation de dérivés d'imidazopyridines pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques
    FR-2727864-A1June 14, 1996SynthelaboUtilisation des ligands des sites de liaison peripherique pour les benzodiazepines pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques
    WO-0139804-A3April 11, 2002Knoll Ag, Martin Villalba Ana, Johannes Schenkel, Susanne Kleber, Roberto TestiGd3 synthesis inhibitors for treating neuropathological disorders